Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

311 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Biodegradable polymer drug-eluting stents reduce the risk of stent thrombosis at 4 years in patients undergoing percutaneous coronary intervention: a pooled analysis of individual patient data from the ISAR-TEST 3, ISAR-TEST 4, and LEADERS randomized trials.
Stefanini GG, Byrne RA, Serruys PW, de Waha A, Meier B, Massberg S, Jüni P, Schömig A, Windecker S, Kastrati A. Stefanini GG, et al. Eur Heart J. 2012 May;33(10):1214-22. doi: 10.1093/eurheartj/ehs086. Epub 2012 Mar 24. Eur Heart J. 2012. PMID: 22447805 Free article.
Long-term outcomes of biodegradable polymer versus durable polymer drug-eluting stents in patients with diabetes a pooled analysis of individual patient data from 3 randomized trials.
de Waha A, Stefanini GG, King LA, Byrne RA, Serruys PW, Kufner S, Meier B, Jüni P, Kastrati A, Windecker S. de Waha A, et al. Among authors: stefanini gg. Int J Cardiol. 2013 Oct 15;168(6):5162-6. doi: 10.1016/j.ijcard.2013.07.263. Epub 2013 Aug 13. Int J Cardiol. 2013. PMID: 23993323
Long-term outcomes of biodegradable versus durable polymer drug-eluting stents in patients with acute ST-segment elevation myocardial infarction: a pooled analysis of individual patient data from three randomised trials.
de Waha A, King LA, Stefanini GG, Byrne RA, Serruys PW, Meier B, Jüni P, Kastrati A, Windecker S. de Waha A, et al. Among authors: stefanini gg. EuroIntervention. 2015 Apr;10(12):1425-31. doi: 10.4244/EIJV10I12A247. EuroIntervention. 2015. PMID: 24602961 Free article.
Report of a European Society of Cardiology-European Association of Percutaneous Cardiovascular Interventions task force on the evaluation of coronary stents in Europe: executive summary.
Byrne RA, Serruys PW, Baumbach A, Escaned J, Fajadet J, James S, Joner M, Oktay S, Jüni P, Kastrati A, Sianos G, Stefanini GG, Wijns W, Windecker S. Byrne RA, et al. Among authors: stefanini gg. Eur Heart J. 2015 Oct 7;36(38):2608-20. doi: 10.1093/eurheartj/ehv203. Epub 2015 Jun 12. Eur Heart J. 2015. PMID: 26071600 Free article. Review.
CAD in TAVI patients: relevance of disease complexity.
Stefanini GG, Panico C. Stefanini GG, et al. EuroIntervention. 2015 Aug;11(4):373-5. doi: 10.4244/EIJV11I4A76. EuroIntervention. 2015. PMID: 26298413 Free article. No abstract available.
Will LEADERS-FREE change my practice? A randomised double-blind comparison of the BioFreedom™ drug-coated stent vs. the Gazelle™ bare metal stent in patients at high bleeding risk using a short (1 month) course of dual antiplatelet therapy.
Stefanini GG, Behan M, Valgimigli M, Oldroyd KG, Leon MB. Stefanini GG, et al. EuroIntervention. 2016 Aug 20;12(6):798-800. doi: 10.4244/EIJV12I6A129. EuroIntervention. 2016. PMID: 27542794 Free article. No abstract available.
311 results